唑来磷酸针与伊班磷酸钠针治疗骨肿瘤的临床对照

目的:探讨唑来磷酸针与伊班磷酸钠针治疗骨肿瘤临床效果,为临床更好治疗骨肿瘤提供依据。方法:选取本院2012年7月－2014年2月我院肿瘤科骨肿瘤患者88例进行研究,按照临床试验数字随机的方法将患者分为A、B两组,其中A组治疗药物为唑来磷酸针(天晴依泰),B组的治疗药物为伊班磷酸钠针(艾本),观察2组治疗后患者疼痛改善情况、不良反应发生情况、治疗费用以及治疗后患者生活质量情况,并对相关数据进行统计学分析。结果:A组治疗后疼痛缓解率为79.55%,显著低于B组的90.91%,差异有统计学意义,P<0.01。A组治疗后的不良反应及患者表现肾毒性明显高于B组,χ²=8.67,P<0.01,差异具有统计学意义。2组费用比较可以看出,唑来磷酸针明显要比伊班磷酸钠针费用高,2组患者的治疗总费用相比,B组更具有经济价值,P<0.01,差异具有统计学意义。A组患者的生活质量(52.27%)较B组(63.64%),P<0.01,差异具有统计学意义。结论:临床上药物治疗骨肿瘤能够很好的改善骨肿瘤患者的生活质量,伊班磷酸钠针治疗骨肿瘤能够明显改善患者的临床骨痛症状,患者治疗费用低,不良反应和毒副作用少,在临床治疗骨肿瘤上具有重要意义,值得在临床上广泛使用。

Comparison of effects of zoledronic acid and ibandronate sodium in patients with bone tumors

OBJECTIVE To investigate clinical effects of zoledronic acid and ibandronate sodium against bone cancer, provide a better basis for clinical treatment of bone tumors.METHODS A total of 88 patients with bone tumors were enrolled from our hospital from July 2012 to February 2014, and divided into group A and B by digital method. Patients in group A received zoledronic acid (Tianqingyitai), in group B received ibandronate sodium (Aiben). Pain improvement, adverse events, treatment costs and quality of life were observed after treatment, and related data were statistically analyzed. RESULTS Pain relief rate was 79.55% in group A, significantly lower than 90.91% in group B, and the difference was significant (P<0.01). Adverse reactions and renal toxicity after treatment were significantly increased in group A than in group B (χ²=8.67, P<0.01). Cost of zoledronic acid was significantly higher than that of ibandronate sodium, so group B was more economic (P<0.01). Quality of life was lower in group A than in group B (P<0.01).CONCLUSION Drug treatment can significantly improve quality of life in patients with bone tumors. Ibandronate sodium can significantly alleviate bone pains due to bone tumors, with low cost, less adverse reactions, toxic and side effects. It has important significance for treatment against bone tumors, and is worthy to be promoted extensively in clinical practice.